Kura Oncology, Inc. (KURA)
NASDAQ: KURA · IEX Real-Time Price · USD
19.23
+0.23 (1.21%)
Apr 26, 2024, 10:47 AM EDT - Market open
Kura Oncology Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Kura Oncology stock have an average target of 28.05, with a low estimate of 10.5 and a high estimate of 37. The average target predicts an increase of 45.87% from the current stock price of 19.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kura Oncology stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +66.41% | Apr 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +66.41% | Mar 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +66.41% | Feb 28, 2024 |
| Wedbush | Wedbush | Buy Reiterates $37 | Buy | Reiterates | $37 | +92.41% | Feb 28, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $22 → $32 | Buy | Maintains | $22 → $32 | +66.41% | Jan 31, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
14.35M
EPS This Year
-2.36
from -2.08
EPS Next Year
-2.51
from -2.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 51.8M | 473.8M | 481.0M | 1.0B |
| Avg | n/a | 14.3M | 139.7M | 178.2M | 361.5M |
| Low | n/a | n/a | 7.6M | 21.6M | 43.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 3,202.2% | 244.4% | 486.4% |
| Avg | - | - | 873.4% | 27.6% | 102.9% |
| Low | - | - | -46.7% | -84.6% | -75.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.10 | -2.04 | 1.27 | 0.89 | 5.23 |
| Avg | -2.36 | -2.51 | -2.06 | -1.42 | 0.03 |
| Low | -2.86 | -3.04 | -3.37 | -3.27 | -2.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.